Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-08-20
M
Mayumi Nakagawa
Federal Grant PI
High Impact
Professor
Also affiliated: Albert Einstein College of Medicine (1986–1990); University of California, San Francisco (1996–2008); Federal Reserve Bank of San Francisco (2004); Hokkaido University (2005); Kyoto University (2014); University of Arkansas Medical Center (2013–2019); Cardiovascular Institute Hospital (1999); Kyoto Prefectural University of Medicine (1995–1999); Blood Systems Research Institute (2004); Shiga University of Medical Science Hospital (2019); Pioneer (Japan) (2023–2024); RIKEN (2020–2025); National Cerebral and Cardiovascular Center (1999); Winthrop Rockefeller Foundation (2024); North Medical Center (2017); Japan Food Research Laboratories (1994); Arkansas Department of Agriculture (2015); Beijing Obstetrics and Gynecology Hospital (2007); Tottori University (1996–2024); Hitachi (Japan) (2004); Kobe University (1999); UConn Health (1990); University of San Francisco (2000); China Medical University (2008–2018); The University of Osaka (2008–2021)
Faculty Researcher
Pathology, College of Medicine
29 h-index
143 pubs
2,832 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Mayumi Nakagawa is a Professor in the Department of Pathology at the University of Arkansas for Medical Sciences, College of Medicine. Her research focuses on understanding and enhancing T-cell responses to high-risk human papillomaviruses (HPVs). This work has been supported by a renewal grant from the National Cancer Institute (NIH) totaling $727,264.
Nakagawa's recent publications investigate various aspects of HPV, including the expansion of HPV-specific T cells in individuals treated with therapeutic vaccines, coinfections with other oncoviruses in HPV-positive individuals, and the evaluation of DNA extraction protocols for studying cervical microbiota from cytology specimens. She also has publications related to cancer prevention measures and has been involved in research on hyperon nucleon scattering and nuclear physics.
With an h-index of 29 and over 2,800 citations across 143 publications, Nakagawa is recognized as a high-impact researcher. She leads a research group and collaborates with colleagues at the University of Arkansas for Medical Sciences, including Sumit K. Shah, Hannah Coleman, Takeo Shibata, and Yong-Chen Lu.
Metrics
- h-index: 29
- Publications: 143
- Citations: 2,832
Selected Publications
-
A ROADMAP FOR LARGE-SCALE CELLULAR THERAPY PRODUCT DISPOSAL (2026)
-
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)
-
Impact of New Hematopoietic Progenitor Cell Collection Goals on Apheresis and Cell Therapy Laboratory Services (2025)
-
AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL (HPC) BOOSTS AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY: IMPACT ON THE CELL THERAPY LABORATORY AND STORAGE FACILITY (2025)
-
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025)
-
Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3. (2024)
-
Coinfections with additional oncoviruses in HPV+ individuals: Status, function and potential clinical implications (2024)
-
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)
-
Assessing the Feasibility of an Online Module for Promoting Cancer Prevention Measures (2021)
-
Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed (2021)
-
Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota (2021)
-
An Online Survey and Focus Groups for Promoting Cancer Prevention Measures (2021)
-
Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed (2020)
-
Examining aspects of successful community-based programs promoting cancer screening uptake to reduce cancer health disparity: A systematic review (2020)
-
Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota (2020)
Federal Grants 1 $727,264 total
NIH
Contact PI
Jul 2010 - Jun 2027
Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- History of CIN-2 in Adolescents (Subcontract with UCSF 4023sc) NIH/Nat. Cancer Institute via University of California, San Francisco Principal Investigator
- CD8 T-cell epitopes of high risk human papillomaviruses American Cancer Society, Inc. Principal Investigator
- Natural History of HPV Infection to Neoplasia (Subcontract with UCSF 4166sc) NIH/Nat. Cancer Institute via University of California, San Francisco Principal Investigator
- MRNA translational Control of Cell Cycle Progression American Cancer Society, Inc. Principal Investigator
- Nakagawa_CPPS Pilot Award UAMS Principal Investigator
- Natural History of HPV-Infection to Neoplasia NIH/Nat. Cancer Institute via University of California, San Francisco Principal Investigator
- CYTOTOXIC T LYMPHOCYTE RESPONSE TO HPV 16 NIH Principal Investigator
Collaboration Network
Top Collaborators
Sumit K. Shah
University of Arkansas for Medical Sciences
5 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- An Online Survey and Focus Groups for Promoting Cancer Prevention Measures
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Assessing the Feasibility of an Online Module for Promoting Cancer Prevention Measures
Takeo Shibata
Kanazawa Medical University
5 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Hannah Coleman
University of Arkansas for Medical Sciences
5 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Teresa Evans
University of Arkansas for Medical Sciences
5 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Milan Bimali
University of Arkansas for Medical Sciences
4 shared publications
In database
- An Online Survey and Focus Groups for Promoting Cancer Prevention Measures
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Assessing the Feasibility of an Online Module for Promoting Cancer Prevention Measures
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
William W. Greenfield
University of Arkansas for Medical Sciences
4 shared publications
In database
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Yong‐Chen Lu
University of Arkansas for Medical Sciences
4 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Jasmine Crane
University of Arkansas for Medical Sciences
4 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Nadia Darwish
University of Arkansas for Medical Sciences
4 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Intawat Nookaew
University of Arkansas for Medical Sciences
4 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
David W. Ussery
University of Arkansas for Medical Sciences
4 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Michael S. Robeson
University of Arkansas for Medical Sciences
3 shared publications
In database
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
Benjamin J. Lieblong
University of Arkansas for Medical Sciences
3 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
Charles M. Quick
University of Arkansas for Medical Sciences
3 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
Jennifer L. Faulkner
Winthrop Rockefeller Foundation
3 shared publications
In database
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Similar Researchers
Based on overlapping research topics
Ruud Dings
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Microbial infections and disease research
Hannah Coleman
University of Arkansas for Medical Sciences
Cervical Cancer and HPV Research
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Brett Daughdrill
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Medical Case Studies
Muthu Veeraputhiran
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Medical Case Studies
Alexia S. Terry
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Host-Pathogen Interactions
Chenghui Li
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Microbial infections and disease research